Your browser doesn't support javascript.
loading
Nivolumab-induced large-duct cholangiopathy treated with ursodeoxycholic acid and tocilizumab.
Reddy, Chanakyaram A; Schneider, Bryan J; Brackett, Lindsay M; Tai, Andrew W.
Affiliation
  • Reddy CA; Division of Gastroenterology & Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
  • Schneider BJ; Division of Hematology & Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
  • Brackett LM; Division of Hematology & Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
  • Tai AW; Division of Gastroenterology & Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Immunotherapy ; 11(18): 1527-1531, 2019 12.
Article in En | MEDLINE | ID: mdl-31789069
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ursodeoxycholic Acid / Bile Duct Diseases / Antibodies, Monoclonal, Humanized / Antineoplastic Agents, Immunological / Nivolumab Type of study: Guideline Limits: Female / Humans / Middle aged Language: En Journal: Immunotherapy Journal subject: ALERGIA E IMUNOLOGIA / TERAPEUTICA Year: 2019 Document type: Article Affiliation country: United States Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ursodeoxycholic Acid / Bile Duct Diseases / Antibodies, Monoclonal, Humanized / Antineoplastic Agents, Immunological / Nivolumab Type of study: Guideline Limits: Female / Humans / Middle aged Language: En Journal: Immunotherapy Journal subject: ALERGIA E IMUNOLOGIA / TERAPEUTICA Year: 2019 Document type: Article Affiliation country: United States Country of publication: United kingdom